6 November 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400001,
Maharashtra, India

The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai 400051,
Maharashtra, India

Scrip Code: 540975

Scrip Symbol: ASTERDM

Dear Sir / Madam,

Subject: **Outcome of Board Meeting held on 6 November 2026 – Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2026**

Ref: **Regulation 33 and 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

In furtherance to our letter dated 28 October 2026 and in accordance with Regulation 33 and 30 of the Listing Regulations, we wish to inform you that the Board of Directors of Aster DM Quality Care Limited ("the Board" and "the Company", respectively) at its meeting held today i.e. 6 November 2026, *inter alia*, has approved unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended 30 September 2026 ("UFRs"), as reviewed and recommended by the Audit Committee. A copy of UFRs, along with the limited review report thereon issued by M/s. Deloitte Haskins & Sells, Statutory Auditors of the Company are enclosed. The UFRs shall be published in the newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors commenced at 01:35 PM (IST) and the above agenda item concluded at 03:56 PM (IST).

This intimation is also being hosted on the website of the Company i.e. www.asterqualitycare.com.

Kindly take the above on records.

Thank you,

Yours faithfully,

For **Aster DM Quality Care Limited**
(Formerly Aster DM Healthcare Limited)

HEMISH PURUSHOTTAM

Digitally signed by HEMISH PURUSHOTTAM
Date: 2026.11.06 16:50:11 +05'30'

_____

Hemish Purushottam
Company Secretary and Compliance Officer
M. No.: A24331

Deloitte
Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru - 560 001
Karnataka, India

Tel: +91 80 6188 6000
Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)** ("the Company"), which includes interim financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust") for the quarter and six months ended 30 September 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listings Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw your attention to Note 3 to the Statement in respect of the Scheme of Amalgamation (the "Scheme") between the Company and Quality Care India Limited ("Transferor Company"), effective from 1 July 2026, as approved by National Company Law Tribunal vide its order dated 19 June 2026. The amalgamation has been accounted in accordance with Indian Accounting Standard ('Ind AS') 103 'Business Combinations' at the carrying value of the assets, liabilities and reserves of the Transferor Company as included in the financial results of the Company. Previous period figures have not been restated. Our opinion is not modified in respect of this matter.

6. The Unaudited Standalone Financial Results includes the interim financial information of the ESOP trust which have not been reviewed by its auditor whose interim financial information reflect total assets of INR 19.56 crores as at 30 September 2026, total revenue of INR 0.23 crores and 0.79 crores, total net profit after tax of INR 0.06 crores and 0.48 crores, total comprehensive income of INR 0.06 crores and 0.48 crores for the quarter and six months ended 30 September 2026 respectively and net cash inflow of INR 2.10 crores for six months ended 30 September 2026, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Company.

   Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For Deloitte Haskins & Sells
Chartered Accountants
(Firm's Registration No. 008072S)

Ankit Daga
(Partner)
(Membership No. 512486)
(UDIN: 26512486MCJZYZ5349)

Place: Bengaluru
Date: 6 November 2026

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Standalone Financial Results for the quarter and six months ended 30 September 2026

(Amount in INR crores)

	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		(Unaudited)					(Audited)
1	**Income**						
	Revenue from operations	1,204.21	725.73	681.81	1,929.94	1,294.85	2,615.70
	Other income	46.12	39.03	44.64	85.15	83.07	155.03
	Total income	**1,250.33**	**764.76**	**726.45**	**2,015.09**	**1,377.92**	**2,770.73**
2	**Expenses**						
	Purchase of medicines and medical consumables	248.86	162.04	141.14	410.90	271.60	530.68
	Changes in inventories	0.77	(12.28)	0.47	(11.51)	(0.09)	8.49
	Professional fees to consultant doctors	284.96	165.48	143.70	450.44	279.92	579.85
	Laboratory outsourcing charges	24.68	21.91	20.95	46.59	38.87	78.55
	Employee benefits expense	193.85	121.39	102.93	315.24	194.41	403.45
	Finance costs	71.66	24.02	22.54	95.68	44.18	87.27
	Depreciation and amortisation expenses	67.23	41.32	39.12	108.55	77.00	154.02
	Other expenses	232.17	120.20	122.81	352.37	226.82	464.30
	Total expenses	**1,124.18**	**644.08**	**593.66**	**1,768.26**	**1,132.71**	**2,306.61**
3	**Profit before exceptional items and tax (1-2)**	**126.15**	**120.68**	**132.79**	**246.83**	**245.21**	**464.12**
4	**Exceptional items (refer Note 5)**	(14.23)	(109.79)	(0.36)	(124.02)	(4.75)	(89.92)
5	**Profit before tax (3+4)**	**111.92**	**10.89**	**132.43**	**122.81**	**240.46**	**374.20**
6	**Tax expenses**						
	Current tax	22.16	35.12	29.77	57.28	58.64	124.37
	Deferred tax	(16.39)	(9.93)	(1.95)	(26.32)	(3.38)	(17.99)
	Total tax expense	**5.77**	**25.19**	**27.82**	**30.96**	**55.26**	**106.38**
7	**Profit/(Loss) for the period / year (5-6)**	**106.15**	**(14.30)**	**104.61**	**91.85**	**185.20**	**267.82**
8	**Other comprehensive income/(loss) for the period / year**						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of net defined benefit liability	(1.74)	-	-	(1.74)	-	0.21
	Income tax relating to items that will not be reclassified to profit or loss	0.44	-	-	0.44	-	(0.05)
	Other comprehensive income/(loss), net of taxes	**(1.30)**	-	-	**(1.30)**	-	**0.16**
9	**Total comprehensive income/(loss) (7+8)**	**104.85**	**(14.30)**	**104.61**	**90.55**	**185.20**	**267.66**
10	Paid-up equity share capital (Face value of INR 10 each)	871.68	518.13	518.13	871.68	518.13	518.13
11	Other equity						3,848.09
12	Earnings/(Loss) per share (Face value of INR 10 each)	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	Basic (in INR)	1.29	(0.28)	2.04	1.37	3.60	5.20
	Diluted (in INR)	1.29	(0.28)	2.03	1.37	3.60	5.19

See accompanying notes to the Statement of Unaudited Standalone Financial Results

Aster DM Quality Care Limited Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Standalone Balance Sheet as at 30 September 2026

(Amount in INR crores)

	Particulars	As at	
		30 September 2026 (Unaudited)	31 March 2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
	Property, plant and equipment	1,962.74	1,051.39
	Right-of-use assets	1,117.78	918.91
	Capital work-in-progress	167.14	160.08
	Goodwill	28.38	-
	Other intangible assets	6.56	2.08
	Financial assets		
	Investments	6,208.14	2,215.67
	Loans	339.60	279.59
	Other financial assets	138.80	124.88
	Income tax assets	156.18	43.93
	Other non-current assets	63.44	32.88
	Total non-current assets	**10,188.76**	**4,829.41**
2	**Current assets**		
	Inventories	75.36	33.24
	Financial assets		
	Trade receivables	462.47	178.94
	Cash and cash equivalents	174.58	119.44
	Bank balances other than cash and cash equivalents above	671.09	1,006.09
	Other financial assets	161.86	139.29
	Other current assets	59.14	33.63
	Total current assets	**1,604.50**	**1,510.63**
	TOTAL ASSETS	**11,793.26**	**6,340.04**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	Equity share capital	871.68	518.13
	Other equity	6,647.45	3,848.09
	Total equity	**7,519.13**	**4,366.22**
2	**Liabilities**		
2(a)	**Non-current liabilities**		
	Financial liabilities		
	Borrowings	1,750.20	239.94
	Lease liabilities	1,265.83	1,014.11
	Other financial liabilities	40.28	-
	Deferred tax liabilities (net)	36.49	30.92
	Other non-current liabilities	38.01	37.88
	Provisions	56.90	19.76
	Total non-current liabilities	**3,187.71**	**1,342.61**
2(b)	**Current liabilities**		
	Financial liabilities		
	Borrowings	355.88	73.74
	Lease liabilities	34.78	19.07
	Trade payables		
	- Total outstanding dues of micro and small enterprises	26.85	21.66
	- Total outstanding dues of creditors other than micro and small enterprises	549.22	270.68
	Other financial liabilities	63.52	205.52
	Other current liabilities	47.76	35.75
	Provisions	8.41	4.79
	Total current liabilities	**1,086.42**	**631.21**
	TOTAL EQUITY AND LIABILITIES	**11,793.26**	**6,340.04**

See accompanying notes to the Statement of Unaudited Standalone Financial Results

Aster DM Quality Care Limited Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Standalone Cash Flows for the six months ended 30 September 2026

(Amount in INR crores)

Particulars	For the six months ended 30 September 2026	For the six months ended 30 September 2025
	(Unaudited)	
Cash flows from operating activities		
Profit before tax for the period	**122.81**	**240.46**
Adjustments for non cash and non operating items :		
Depreciation and amortisation expenses	108.55	77.00
Finance costs	95.68	44.18
Dividend income on non-current investments	(27.45)	(11.95)
Interest income and other non-operating income	(51.20)	(68.76)
Allowances for credit losses on financial assets	27.55	3.97
Equity settled share based payment	3.85	4.36
Impact of lease modification	0.84	-
Loss on sale of property, plant and equipment (net)	(0.57)	2.15
Operating cash flows before movements in working capital	**280.06**	**291.41**
Working capital adjustments :		
Changes in trade receivables	(62.73)	(39.49)
Changes in inventories	(11.50)	(0.09)
Changes in other financial assets	(33.66)	(19.53)
Changes in other assets	(5.93)	(8.88)
Changes in trade payables	114.08	24.72
Changes in provisions	4.82	3.31
Changes in other financial liabilities	(46.91)	1.79
Changes in other liabilities	(7.18)	6.88
Cash generated from operating activities	**231.05**	**260.12**
Taxes paid, net of refund received	(69.88)	(30.20)
Net cash generated from operating activities (A)	**161.17**	**229.92**
Cash flows from investing activities		
Movement in other bank balances and restricted deposits	337.70	133.25
Redemption of /(Investment in) subsidiaries and associates (net)	(130.67)	(162.50)
Interest received	64.64	51.19
Dividend received	27.45	11.95
Payment to acquire intangible assets	(1.19)	(0.36)
Payment to acquire property, plant and equipment (including capital work-in-progress)	(160.93)	(70.91)
Loan to subsidiary and associate (net of loan repayment)	(56.91)	(40.53)
Proceeds on sale of property, plant and equipment	1.57	0.98
Net cash generated from / (used in) investing activities (B)	**81.66**	**(76.93)**
Cash flows from financing activities		
Payment of lease liabilities	(55.56)	(48.77)
Finance cost paid	(54.84)	(17.14)
Dividend paid	(155.06)	(51.69)
Proceeds from exercise of share options	4.10	2.23
Long term secured loans availed	43.37	6.41
Long term secured loans repaid	(82.38)	(40.37)
Current borrowings (repaid)/availed, net	84.76	-
Net cash used in financing activities (C)	**(215.61)**	**(149.33)**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**27.22**	**3.66**
Cash and cash equivalents at the beginning of the period	119.44	119.84
Cash and cash equivalents on account of amalgamation	27.92	-
Cash and cash equivalents at the end of the period	**174.58**	**123.50**

Components of cash and cash equivalents

Particulars	For the six months ended 30 September 2026	For the six months ended 30 September 2025
Cash and cash equivalents comprises of :		
a) Cash on hand	1.83	1.43
b) Balance with banks	172.72	122.02
c) Cash /Cheques- in transit	0.03	0.05
Total	**174.58**	**123.50**

Changes in liabilities arising from financing activities for the period ended 30 September 2026

Particulars	As at	Movement during the period						As at
	01 April 2026	On account of amalgamation	Cash inflows	Cash outflows	Additions/ Modifications	Non cash changes	Finance costs	30 September 2026
Borrowings (Current and Non-current) including interest	313.84	1,747.02	128.13	(137.22)	-	0.47	56.78	2,109.02
Lease liabilities	1,033.18	270.06	-	(55.56)	5.34	8.69	38.90	1,300.61
Total	**1,347.02**	**2,017.08**	**128.13**	**(192.78)**	**5.34**	**9.16**	**95.68**	**3,409.63**

Changes in liabilities arising from financing activities for the period ended 30 September 2025

Particulars	As at	Movement during the period						As at
	01 April 2025	On account of amalgamation	Cash inflows	Cash outflows	Additions/ Modifications	Non cash changes	Finance costs	30 September 2025
Borrowings (Current and Non-current) including interest	377.66	-	6.41	(57.51)	-	-	17.06	343.62
Lease liabilities	822.58	-	-	(48.77)	78.08	8.33	27.12	887.34
Total	**1,200.24**	**-**	**6.41**	**(106.28)**	**78.08**	**8.33**	**44.18**	**1,230.96**

Note : The above Statement of Unaudited Standalone Cash Flows has been prepared under the 'Indirect method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Aster DM Quality Care Limited
Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Unaudited Standalone Financial Results:

1) The Statement of Unaudited Standalone Financial Results of Aster DM Quality Care Limited ('the Company'), which includes the financial information of DM Healthcare Employees Welfare Trust (the 'ESOP Trust'), for the quarter and six months ended 30 September 2026 ('the Statement') has been reviewed by the Audit Committee and approved by the Board of Directors on 06 November 2026. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company, who have expressed an unmodified review conclusion.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

3) On 11 December 2025, the Company had submitted the Scheme of Amalgamation ('Scheme') by way of merger of Quality Care India Limited (Transferor Company/QCIL) with Aster DM Healthcare Limited (Transferee Company/the Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for its approval. The Scheme was sanctioned by the NCLT on 19 June 2026. On 26 June 2026, the Applicant Companies filed the approvals and other documents with the Registrar of Companies, Telangana. Upon such filing and completion of all other conditions precedent as mentioned in the Scheme, the Scheme became effective from 01 July 2026, being the first day of the calendar month immediately following the month in which all such conditions are fulfilled. As per the terms of the Scheme, the name of the Company has been changed from "Aster DM Healthcare Limited" to "Aster DM Quality Care Limited" and all the assets, liabilities and reserves of the Transferor Company have been transferred to and vested in the Company.

   Consequent to the Scheme coming into effect and in accordance with the Share Exchange Ratio prescribed in the Scheme, on 13 July 2026 the Company allotted its 353,551,410 equity shares of INR 10/- each (fully paid-up) to the equity shareholders of erstwhile QCIL as on the 'Record Date' fixed for the said purpose.

   As per the terms of the Scheme, the amalgamation has been accounted by applying principles of 'pooling of interests' method as laid down in Indian Accounting Standard ('Ind AS') 103 'Business Combinations' prescribed under section 133 of the Companies Act, 2013 and the Companies (Indian Accounting Standards) Rules, 2015. Accordingly, the financial results for the quarter and half year ended 30 September 2026 include the results of QCIL for the period from 01 July 2026 to 30 September 2026. The figures for the previous periods/year have not been restated and therefore, are not comparable with those of the immediately preceding quarter and the corresponding periods of the previous year.

4) The Company acquired additional 9.00% stake in its subsidiary United Ciigma Institute of Medical Sciences Private Limited, from minority shareholder on 10 September 2026 for an amount of INR 30.69 crores. Consequent to the said acquisition, shareholding of the Company in United Ciigma Institute of Medical Sciences Private Limited has increased from 76.00% as at 01 July 2026 to 85.00% as at 30 September 2026.

5) The Company incurred non-recurring expenses of INR 14.23 crores and INR 124.02 crores during the quarter and six months ended 30 September 2026, respectively, towards professional fees and such other costs relating to the merger. The same has been presented as Exceptional Items in the Statement.

6) The Board of Directors of the Company, at its meeting held on 30 January 2026, approved the Aster DM Quality Care Limited Employees Stock Option Scheme 2026 ("ESOP Scheme 2026"). The ESOP Scheme 2026 was approved by the shareholders of the Company on 26 September 2026 through postal ballot in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

7) In accordance with Ind AS 108, Operating Segments, segment information has been provided in the Statement of Unaudited Consolidated Financial Results of the Company and therefore no separate disclosure on segment information is given in the Statement of Unaudited Standalone Financial Results.

8) The 'Statement of Unaudited Standalone Balance Sheet as at 30 September 2026' and the 'Statement of Unaudited Standalone Cash Flows for the six months ended 30 September 2026' forms part of the Notes to 'Statement of Unaudited Standalone Financial Results for the quarter and six months ended 30 September 2026'.

9) Statement of Unaudited Standalone Financial Results are available for perusal at the website of the Company and the stock exchanges.

For and on behalf of the Board of Directors of
Aster DM Quality Care Limited
CIN : L85110TS2008PLC207383

Varun Khanna
Managing Director & Group Chief Executive Officer
DIN 03584124
Bengaluru
06 November 2026

Aster DM Quality Care Limited Bengaluru

Deloitte Haskins & Sells

Chartered Accountants
Prestige Trade Tower, Level 19
46, Palace Road, High Grounds
Bengaluru - 560 001
Karnataka, India

Tel: +91 80 6188 6000
Fax: +91 80 6188 6011

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **ASTER DM QUALITY CARE LIMITED (formerly known as ASTER DM HEALTHCARE LIMITED)** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its joint venture and associates for the quarter and six months ended 30 September 2026 ("the Statement") which includes the financial information of DM Healthcare Employees Welfare Trust (the "ESOP trust") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the entities as provided in Annexure 1.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 2 subsidiaries included in the Unaudited Consolidated Financial Results, whose interim financial information reflect total assets of INR 1,526.61 crores as at 30 September 2026, total revenues of INR 294.54 crores, total net profit after tax of INR 52.80 crores, total comprehensive income of INR 48.25 crores for the quarter and six months ended 30 September 2026 and net cash inflows of 52.42 crores for six months ended 30 September 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion on the Statement is not modified in respect of these matters.

7. The Unaudited Consolidated Financial Results includes the interim financial information of 20 subsidiaries and ESOP trust which have not been reviewed by their auditors, whose interim financial information reflect total assets of INR 3,697.42 crores as at 30 September 2026, total revenue of INR 77.03 crores and 138.56 crores, total loss after tax of INR 6.74 crores and 11.15 crores, total comprehensive loss of INR 6.71 crores and 11.12 crores for the quarter and six months ended 30 September 2026 respectively and net cash inflows of INR 36.44 for the six months ended 30 September 2026 as considered in the Statement. The Unaudited Consolidated Financial Results also include the Group's share of net profit after tax of INR 2.13 crores and 2.28 crores and total comprehensive income of INR 2.13 crores and 2.28 crores for the quarter and six months ended 30 September 2026, as considered in the Statement, in respect of 1 joint venture and 3 associates based on their interim financial information which have not been reviewed by their auditors.

   According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)



Ankit Daga
Partner
(Membership No. 512486)
(UDIN: 26512486FQSPES3228)

Place: Bengaluru
Date: 6 November 2026

Annexure 1 – List of entities included in the Unaudited Consolidated Financial Results

S.No	Entity	Relationship	Country of incorporation
1	Aster DM Quality Care Limited (formerly known as Aster DM Healthcare Limited)	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Sri Sainatha Multispeciality Hospitals Private Limited	Wholly owned Subsidiary	India
5	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
6	Aster DM Super-Specialty Hospital Private Limited (formerly known as Aster DM Super-Specialty Hospitals (Yeswanthpur) Private Limited)	Wholly owned Subsidiary (w.e.f. 28 July 2025)	India
7	Convenient Hospitals Limited ^	Wholly owned Subsidiary	India
8	Culinary Cure Foods Private Limited ^	Wholly owned Subsidiary	India
9	Quality Care Jharsuguda Private Limited ^	Wholly owned Subsidiary	India
10	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
11	Chemistry Intermediary Holdings Limited ^	Wholly owned Subsidiary	Mauritius
12	Malabar Institute of Medical Sciences Limited	Subsidiary	India
13	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
14	Prerana Hospital Limited	Subsidiary	India
15	Hindustan Pharma Distributors Private Limited	Subsidiary	India
16	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Subsidiary	India
17	Aster DM Super-Specialty Hospital (Sarjapur) Private Limited	Subsidiary	India
18	Ganga Care Hospital Limited ^	Subsidiary	India
19	Ramkrishna Care Medical Sciences Private Limited ^	Subsidiary	India

S.No	Entity	Relationship	Country of incorporation
20	United Ciigma Institute of Medical Sciences Private Limited ^	Subsidiary	India
21	KIMS Health Care Management Limited ^	Subsidiary	India
22	EMED Human Resources India Private Limited	Step down Subsidiary	India
23	Ezhimala Infrastructure LLP	Step down Subsidiary	India
24	Warseps Healthcare LLP	Step down Subsidiary	India
25	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
26	Aster Ramesh Duhita LLP	Step down Subsidiary	India
27	Komali Fertility Centre LLP	Step down Subsidiary	India
28	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
29	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
30	Cantown Infra Developers LLP	Step down Subsidiary	India
31	Aasraya Healthcare LLP	Step down Subsidiary	India
32	Heart Care Institute And Research Centre (Indore) Private Limited ^	Step down Subsidiary	India
33	QCIL Nagpur Private Limited ^	Step down Subsidiary	India
34	Ciigma Institute of Medical Sciences Private Limited ^	Step down Subsidiary	India
35	United Ciigma Hospitals Healthcare Private Limited ^	Step down Subsidiary	India
36	KIMS Kottayam Institute of Medical Science Private Limited (formerly known as KIMS Bellerose Institute of Medical Science Private Limited) ^	Step down Subsidiary	India
37	KIMS Kollam Multi Speciality Hospital India Private Limited ^	Step down Subsidiary	India
38	Spiceretreat Hospitality Services Private Limited ^	Step down Subsidiary	India
39	KIMSHEALTH Executive Leisure Private Limited ^	Step down Subsidiary	India
40	KIMS Al Shifa Healthcare Private Limited ^	Step down Subsidiary	India
41	KIMS Nagercoil Institute of Medical Sciences Private Limited ^	Step down Subsidiary	India
42	STS Holdings Limited ^	Step down Subsidiary	Bangladesh
43	STS Hospital Chittagong Limited ^	Step down Subsidiary	Bangladesh

S.No	Entity	Relationship	Country of incorporation
44	DM Healthcare Employees Welfare Trust	Trust	India
45	Quality Care Health Services India Private Limited ^	Joint Venture	India
46	MIMS Infrastructure and Properties Private Limited	Associate	India
47	Mindriot Research and Innovation Foundation	Associate	India
48	Alfaone Medicals Private Limited	Associate	India
49	Alfaone Retail Pharmacies Private Limited	Associate	India
50	SCL Healthcare Private Limited ^	Associate	India

^ with effect from 01 July 2026, on account of amalgamation

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2026

(Amount in INR crores)

	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		(Unaudited)					(Audited)
1	**Income**						
	Revenue from operations	2,829.20	1,310.68	1,197.21	4,139.88	2,275.08	4,643.22
	Other income	51.53	37.03	28.25	88.56	61.43	125.60
	Total income	**2,880.73**	**1,347.71**	**1,225.46**	**4,228.44**	**2,336.51**	**4,768.82**
2	**Expenses**						
	Purchase of medicines and medical consumables	610.33	300.37	271.05	910.70	518.20	1,047.61
	Changes in inventories	2.41	(8.60)	(0.04)	(6.19)	(0.05)	1.18
	Professional fees to consultant doctors	622.36	295.14	257.15	917.50	496.85	1,031.87
	Laboratory outsourcing charges	19.00	9.22	6.13	28.22	13.89	27.52
	Employee benefits expense	465.65	242.20	211.92	707.85	406.73	848.09
	Finance costs	118.98	31.21	30.76	150.19	61.53	122.98
	Depreciation and amortisation expenses	149.66	69.29	66.12	218.95	129.34	264.25
	Other expenses	446.04	208.03	201.16	654.07	382.26	785.92
	Total expenses	**2,434.43**	**1,146.86**	**1,044.25**	**3,581.29**	**2,008.75**	**4,129.42**
3	**Profit before share of loss of equity accounted investees, exceptional items and tax (1-2)**	**446.30**	**200.85**	**181.21**	**647.15**	**327.76**	**639.40**
4	Share of loss of equity accounted investees	(8.00)	(8.39)	(14.00)	(16.39)	(19.72)	(37.00)
5	Exceptional items (Refer Note 6)	(18.95)	(114.38)	(0.36)	(133.33)	(4.75)	(32.71)
6	**Profit before tax (3+4+5)**	**419.35**	**78.08**	**166.85**	**497.43**	**303.29**	**569.69**
7	**Tax expense**						
	Current tax	106.54	56.98	46.54	163.52	90.52	186.03
	Deferred tax	(9.57)	(8.18)	(1.00)	(17.75)	(2.10)	(43.44)
	Total tax expense	**96.97**	**48.80**	**45.54**	**145.77**	**88.42**	**142.59**
8	**Profit for the period/ year (6-7)**	**322.38**	**29.28**	**121.31**	**351.66**	**214.87**	**427.10**
9	**Other comprehensive income/ (loss) for the period/ year**						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of net defined benefit liability	(7.94)	-	-	(7.94)	-	(0.22)
	Income tax on items that will not be reclassified subsequently to profit or loss	2.22	-	-	2.22	-	0.05
	Items that will be reclassified subsequently to profit or loss						
	Exchange difference in translating financial statements of foreign operations	15.50	0.14	0.29	15.64	(0.25)	0.73
	Income tax on items that will be reclassified subsequently to profit or loss	-	(0.04)	(0.08)	(0.04)	0.06	(0.20)
	Other comprehensive income/ (loss), net of taxes	**9.78**	**0.10**	**0.21**	**9.88**	**(0.19)**	**0.36**
10	**Total comprehensive income (8+9)**	**332.16**	**29.38**	**121.52**	**361.54**	**214.68**	**427.46**
11	**Profit attributable to :**						
	Owners of the Company	262.02	16.06	110.00	278.08	195.52	388.14
	Non-controlling interests	60.36	13.22	11.31	73.58	19.35	38.96
	Profit for the period/ year	**322.38**	**29.28**	**121.31**	**351.66**	**214.87**	**427.10**
12	**Other comprehensive income attributable to :**						
	Owners of the Company	8.42	0.10	0.21	8.52	(0.19)	0.38
	Non-controlling interests	1.36	-	-	1.36	-	(0.02)
	Other comprehensive income/ (loss) for the period/ year	**9.78**	**0.10**	**0.21**	**9.88**	**(0.19)**	**0.36**
13	**Total comprehensive income attributable to :**						
	Owners of the Company	270.44	16.16	110.21	286.60	195.33	388.52
	Non-controlling interests	61.72	13.22	11.31	74.94	19.35	38.94
	Total comprehensive income for the period/ year	**332.16**	**29.38**	**121.52**	**361.54**	**214.68**	**427.46**
14	Paid-up equity share capital (Face value of INR 10 each)	871.68	518.13	518.13	871.68	518.13	518.13
15	Other equity						4,057.73
16	Earnings per share (Face value of INR 10 each) from	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	Basic	3.19	0.31	2.13	4.14	3.80	7.53
	Diluted	3.19	0.31	2.13	4.13	3.80	7.52

See accompanying notes to the Statement of Unaudited Consolidated Financial Results

Aster DM Quality Care Limited Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Consolidated Balance Sheet as at 30 September 2026

(Amount in INR crores)

	Particulars	As at	
		30 September 2026 (Unaudited)	31 March 2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
	Property, plant and equipment	6,707.90	2,618.74
	Right-of-use assets	1,778.07	1,339.54
	Capital work-in-progress	529.14	412.59
	Investment Property	15.34	-
	Goodwill	2,721.10	264.12
	Other intangible assets	978.54	19.25
	Intangible asset under development	4.36	7.02
	Financial assets		
	Investments	338.13	1,165.15
	Loans	2.97	1.25
	Other financial assets	242.21	136.27
	Income tax assets	230.98	73.80
	Deferred tax assets	137.17	36.20
	Other non-current assets	216.41	90.24
	Total non-current assets	**13,902.32**	**6,164.17**
2	**Current assets**		
	Inventories	217.59	91.16
	Financial assets		
	Investments	83.79	1.41
	Trade receivables	841.39	307.23
	Cash and cash equivalents	776.15	228.07
	Bank balances other than cash and cash equivalents above	1,380.01	1,097.29
	Other financial assets	213.92	158.60
	Other current assets	107.62	64.03
	Total current assets	**3,620.47**	**1,947.79**
	TOTAL ASSETS	**17,522.79**	**8,111.96**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	Equity share capital	871.68	518.13
	Instruments entirely equity in nature	19.34	-
	Other equity	6,899.39	4,057.73
	Total equity attributable to owners of the Company	**7,790.41**	**4,575.86**
2	Non-controlling interests	1,439.08	257.84
	Total equity	**9,229.49**	**4,833.70**
3	**Liabilities**		
3(a)	**Non-current liabilities**		
	Financial liabilities		
	Borrowings	3,410.16	558.44
	Lease liabilities	1,927.52	1,488.83
	Other financial liabilities	50.73	3.78
	Deferred tax liabilities	568.06	132.82
	Other non-current liabilities	64.64	61.80
	Provisions	140.62	53.43
	Total non-current liabilities	**6,161.73**	**2,299.10**
3(b)	**Current liabilities**		
	Financial liabilities		
	Borrowings	548.86	142.74
	Lease liabilities	53.85	29.65
	Trade payables		
	- Total outstanding dues of micro and small enterprises	87.95	44.42
	- Total outstanding dues of creditors other than micro and small enterprises	1,034.47	437.09
	Other financial liabilities	186.76	89.96
	Income tax liabilities	57.42	0.01
	Other current liabilities	134.99	223.23
	Provisions	27.27	12.06
	Total current liabilities	**2,131.57**	**979.16**
	TOTAL EQUITY AND LIABILITIES	**17,522.79**	**8,111.96**

See accompanying notes to the Statement of Unaudited Consolidated Financial Results

Aster DM Quality Care Limited Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Consolidated Cash Flows for the six months ended 30 September 2026

(Amount in INR crores)

Particulars	For the six months ended 30 September 2026 (Unaudited)	For the six months ended 30 September 2025 (Unaudited)
Cash flows from operating activities		
Profit before tax for the period	**497.43**	**303.29**
Adjustments for		
Depreciation and amortisation expenses	218.95	129.34
Fair value (gain)/loss on derivatives	-	(0.50)
Loss on sale of property, plant and equipment	(0.29)	2.46
Allowance for credit loss on financial assets	36.82	5.09
Profit on sale of investment	(0.45)	-
Equity settled share based payment	3.85	4.36
Share of loss of equity accounted investees	16.39	19.72
Finance costs	150.19	61.53
Dividend Income	(14.24)	-
Interest and other non operating income	(57.60)	(55.81)
Operating profit before working capital changes	**851.05**	**469.48**
Working capital changes		
Changes in inventories	(5.23)	(0.05)
Changes in trade receivable	(118.72)	(60.52)
Changes in other financial assets and other assets	(43.48)	(87.18)
Changes in other financial liabilities, trade payables, provisions and other liabilities	117.76	66.42
Cash generated from operations	**801.38**	**388.15**
Income tax paid, net	(170.12)	(68.95)
Net cash generated from operating activities (A)	**631.26**	**319.20**
Cash flows from investing activities		
Acquisition of property, plant and equipment and capital work-in-progress	(432.28)	(231.90)
Acquisition of other intangible assets	(5.05)	(3.09)
Proceeds from disposal of property, plant and equipment	1.82	1.09
Dividend received	14.24	-
Interest received	79.91	50.92
Redemption of / (Investment) in mutual fund (net)	(12.41)	-
Investments/ loans given to related parties	(29.06)	(3.43)
Movement in other bank balances and restricted deposits	729.22	111.63
Net cash generated from / (used in) investing activities (B)	**346.39**	**(74.78)**
Cash flows from financing activities		
Proceeds from exercise of share options	4.10	2.23
Proceeds from instruments entirely equity in nature	19.34	-
Non-current borrowings availed	57.85	63.23
Non-current borrowings repaid	(121.71)	(68.89)
Current borrowings movement, (net)	74.01	2.96
Lease payments	(78.88)	(65.62)
Acquisition of non-controlling interests	(559.39)	(66.43)
Dividend paid to non-controlling interest	(2.74)	(2.31)
Dividend paid to owners	(155.06)	(51.69)
Finance cost paid	(80.28)	(27.00)
Net cash used in financing activities (C)	**(842.76)**	**(213.52)**
Net increase in cash and cash equivalents (A+B+C)	**134.89**	**30.90**
Cash and cash equivalents at the beginning of the Period	228.07	164.59
Addition on account of amalgamation	410.49	-
Effect of exchange rate changes on cash and cash equivalents at the end of the period	2.70	0.10
Cash and cash equivalents at the end of the period	**776.15**	**195.59**

See accompanying notes to the Statement of Unaudited Consolidated Financial Results

Components of cash and cash equivalents

Particulars	As at 30 September 2026 (Unaudited)	As at 30 September 2025 (Unaudited)
Cash and cash equivalents comprises of :		
a) Cash on hand	7.59	4.82
b) Balance with banks	768.15	190.56
c) Cash-in-transit / cheques in hand	0.41	0.21
Total	**776.15**	**195.59**

Aster DM Quality Care Limited Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Statement of Unaudited Consolidated Cash Flows for the six months ended 30 September 2026 (continued)

(Amount in INR crores)

Changes in financial liabilities arising from financing activities

Particulars	As at 01 April 2026	On account of amalgamation	Movement during the period						As at 30 September 2026
			Cash inflows	Cash outflows	Addition/ Modifications	Foreign exchange Movement	Non cash changes	Finance cost	
Borrowings (Current and Non-current) including interest	703.87	3,269.18	131.86	(201.99)	-	-	13.28	103.58	4,019.78
Lease liabilities	1,518.48	456.72	-	(78.88)	16.45	-	21.99	46.61	1,981.37
Total	**2,222.35**	**3,725.90**	**131.86**	**(280.87)**	**16.45**	**-**	**35.27**	**150.19**	**6,001.15**

Particulars	As at 01 April 2025	On account of amalgamation	Movement during the period						As at 30 September 2025
			Cash inflows	Cash outflows	Addition/ Modifications	Foreign exchange Movement	Non cash changes	Finance cost	
Borrowings (Current and Non-current) including interest	643.91	-	66.19	(95.89)	-	-	3.64	24.15	642.00
Lease liabilities	1,375.59	-	-	(65.62)	81.58	-	21.08	37.38	1,450.01
Total	**2,019.50**	**-**	**66.19**	**(161.51)**	**81.58**	**-**	**24.72**	**61.53**	**2,092.01**

Note : The above statement of cash flows has been prepared under the 'Indirect method' as set out in Ind AS 7, 'Statement of Cash Flows'.
See accompanying notes to the Statement of Unaudited Consolidated Financial Results

Aster DM Quality Care Limited Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Notes to the Statement of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2026:

1) The Statement of Unaudited Consolidated Financial Results of Aster DM Quality Care Limited ('the Parent Company'/'Company') and its subsidiaries (together referred to as 'the Group'), DM Healthcare Employees Welfare Trust (the 'ESOP Trust') and its share of loss in joint venture and associates for the quarter and six months ended 30 September 2026 ('the Statement') has been reviewed by the Audit Committee and approved by the Board of Directors on 06 November 2026. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Parent Company, who have expressed an unmodified review conclusion.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

3) On 11 December 2025, the Parent Company had submitted the Scheme of Amalgamation ('Scheme') by way of merger of Quality Care India Limited (Transferor Company/QCIL) with Aster DM Healthcare Limited (Transferee Company/the Company) (the 'Applicant Companies') to the National Company Law Tribunal ('NCLT') for its approval. The Scheme was sanctioned by the NCLT on 19 June 2026. On 26 June 2026, the Applicant Companies filed the approvals and other documents with the Registrar of Companies, Telangana. Upon such filing and completion of all other conditions precedent as mentioned in the Scheme, the Scheme became effective from 01 July 2026, being the first day of the calendar month immediately following the month in which all such conditions are fulfilled. As per the terms of the Scheme, the name of the Parent Company has been changed from "Aster DM Healthcare Limited" to "Aster DM Quality Care Limited" and all the assets, liabilities and reserves of the Transferor Company have been transferred to and vested in the Parent Company.

   Consequent to the Scheme coming into effect and in accordance with the Share Exchange Ratio prescribed in the Scheme, on 13 July 2026 the Parent Company allotted its 353,551,410 equity shares of INR 10/- each (fully paid-up) to the equity shareholders of erstwhile QCIL as on the 'Record Date' fixed for the said purpose.

   As per the terms of the Scheme, the amalgamation has been accounted by applying principles of 'pooling of interests' method as laid down in Indian Accounting Standard ('Ind AS') 103 'Business Combinations' prescribed under section 133 of the Companies Act, 2013 and the Companies (Indian Accounting Standards) Rules, 2015. Accordingly, the financial results for the quarter and half year ended 30 September 2026 include the results of QCIL for the period from 01 July 2026 to 30 September 2026. The figures for the previous periods/year have not been restated and therefore, are not comparable with those of the immediately preceding quarter and the corresponding periods of the previous year.

4) The Parent Company acquired additional 9.00% stake in its subsidiary United Ciigma Institute of Medical Sciences Private Limited, from minority shareholder on 10 September 2026 for an amount of INR 30.69 crores. Consequent to the said acquisition, shareholding of the Parent Company in United Ciigma Institute of Medical Sciences Private Limited has increased from 76.00% as at 01 July 2026 to 85.00% as at 30 September 2026.

5) The subsidiary of the Parent Company, Chemistry Intermediate Holdings Limited, acquired an additional 14.21% stake in its step-down subsidiary, STS Holdings Limited, from minority shareholders on 18 August 2026 for a consideration of INR 495.23 crores. Consequently, the Group's shareholding in STS Holdings Limited increased from 60.12% as at 1 July 2026 to 74.33% as at 30 September 2026.

6) The Group incurred non-recurring expenses of INR 18.95 crores and INR 133.33 crores during the quarter and six months ended 30 September 2026, respectively, towards professional fees and such other costs relating to the merger. The same has been presented as Exceptional Items in the Statement.

7) The Board of Directors of the Parent Company, at its meeting held on 30 January 2026, approved the Aster DM Quality Care Limited Employees Stock Option Scheme 2026 ("ESOP Scheme 2026"). The ESOP Scheme 2026 was approved by the shareholders of the Parent Company on 26 September 2026 through postal ballot in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

8) Segment details of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2026

(Amount in INR crores)

	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		(Unaudited)					(Audited)
1	**Segment revenue**						
	Hospitals & Clinics	2,772.84	1,277.63	1,160.37	4,050.47	2,203.05	4,506.39
	Others	112.91	73.45	75.50	186.36	143.06	276.61
	Total	**2,885.75**	**1,351.08**	**1,235.87**	**4,236.83**	**2,346.11**	**4,783.00**
	Less: Inter-segment revenue	56.55	40.40	38.66	96.95	71.03	139.79
	Revenue from operations	**2,829.20**	**1,310.68**	**1,197.21**	**4,139.88**	**2,275.08**	**4,643.21**
	Segment results before tax, exceptional items and finance cost						
	Hospitals & Clinics	544.64	238.92	231.23	783.56	414.37	780.42
	Others	13.01	2.83	(14.72)	15.84	(29.32)	(1.37)
	Total	**557.65**	**241.75**	**216.51**	**799.40**	**385.05**	**779.05**
	Adjustment :						
	Finance cost	(118.98)	(31.21)	(30.76)	(150.19)	(61.53)	(122.98)
	Share of loss of equity accounted investees	(8.00)	(8.39)	(14.00)	(16.39)	(19.72)	(37.00)
	Other unallocable expenditure net of unallocable income (including adjustment of exceptional items)	(11.32)	(124.07)	(4.90)	(135.39)	(0.51)	(49.38)
	Profit before tax	**419.35**	**78.08**	**166.85**	**497.43**	**303.29**	**569.69**
1	**Segment assets**						
	Hospitals & Clinics	16,315.36	6,995.03	6,416.85	16,315.36	6,416.85	6,732.99
	Others	453.45	347.36	266.71	453.45	266.71	335.11
	Unallocated	753.98	859.05	1,124.73	753.98	1,124.73	1,043.86
	Total	**17,522.79**	**8,201.44**	**7,808.29**	**17,522.79**	**7,808.29**	**8,111.96**
2	**Segment liabilities**						
	Hospitals & Clinics	8,051.04	3,027.60	2,908.18	8,051.04	2,932.11	2,952.02
	Others	86.76	73.07	30.73	86.76	30.73	72.88
	Unallocated	155.50	246.17	97.87	155.50	73.94	253.36
	Total	**8,293.30**	**3,346.84**	**3,036.78**	**8,293.30**	**3,036.78**	**3,278.26**

Note - During the quarter ended 30 September 2026, the Group revised its operating segment classification to align with the manner in which the Chief Operating Decision Maker (CODM) reviews the Group's performance. Accordingly, the Labs and Pharmacies segments have been regrouped under 'Others', resulting in only two reportable segments: 'Hospitals & Clinics' and 'Others'. Comparative figures have been reclassified to reflect the revised segment presentation.

9) The 'Statement of Unaudited Consolidated Balance Sheet as at 30 September 2026' and the 'Statement of Unaudited Consolidated Cash Flows for the six months ended 30 September 2026' forms part of the Notes to 'Statement of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2026'.

10) Statements of Unaudited Standalone and Consolidated Financial Results are available for perusal at the website of the Parent Company and the stock exchanges.

For and on behalf of the Board of Directors of
Aster DM Quality Care Limited
CIN : L85110TS2008PLC207383

Varun Khanna
Managing Director & Group Chief Executive Officer
DIN 03584124
Bengaluru
06 November 2026

Aster DM Quality Care Limited Bengaluru

Aster DM Quality Care Limited
(Formerly known as Aster DM Healthcare Limited)
CIN : L85110TS2008PLC207383
Registered office : No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Annexure A to Statement of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2026

Sl No	Entity	Relationship	Country of incorporation
1	Aster DM Quality Care Limited (Formerly known as Aster DM Healthcare Limited)	Parent	India
2	DM Med City Hospitals (India) Private Limited	Wholly owned Subsidiary	India
3	Ambady Infrastructure Private Limited	Wholly owned Subsidiary	India
4	Aster DM Multispecialty Hospital Private Limited (formerly known as Aster DM Healthcare (Trivandrum) Private Limited)	Subsidiary	India
5	Sri Sainatha Multispeciality Hospitals Private Limited	Wholly owned Subsidiary	India
6	Aster Clinical Lab LLP	Wholly owned Subsidiary	India
7	Aster DM Super-Specialty Hospital (Sarjapur) Private Limited	Subsidiary	India
8	Aster DM Super-Specialty Hospital Private Limited (formerly known as Aster DM Super-Specialty Hospital (Yeswanthpur) Private Limited)	Wholly owned Subsidiary (w.e.f. July 28, 2025)	India
9	DM Healthcare Employees Welfare Trust	Trust	India
10	Culinary Cure Foods Private Limited	Wholly owned Subsidiary*	India
11	Quality Care Jharsuguda Private Limited	Wholly owned Subsidiary*	India
12	Affinity Holdings Private Limited	Wholly owned Subsidiary	Mauritius
13	Chemistry Intermediate Holdings Limited	Wholly owned Subsidiary*	Mauritius
14	Convenient Hospitals Limited	Wholly owned Subsidiary*	India
15	Malabar Institute of Medical Sciences Limited	Subsidiary	India
16	Dr. Ramesh Cardiac and Multispeciality Hospitals Private Limited	Subsidiary	India
17	Prerana Hospital Limited	Subsidiary	India
18	Hindustan Pharma Distributors Private Limited	Subsidiary	India
19	Ganga Care Hospital Limited	Subsidiary*	India
20	Ramkrishna Care Medical Sciences Private Limited	Subsidiary*	India
21	United Ciigma Institute of Medical Sciences Private Limited	Subsidiary*	India
22	KIMS Health Care Management Limited	Subsidiary*	India
23	EMED Human Resources India Private Limited	Step down Subsidiary	India
24	Ezhimala Infrastructure LLP	Step down Subsidiary	India
25	Warseps Healthcare LLP	Step down Subsidiary	India
26	Sanghamitra Hospitals Private Limited	Step down Subsidiary	India
27	Aster Ramesh Duhita LLP	Step down Subsidiary	India
28	Komali Fertility Centre LLP	Step down Subsidiary	India
29	Komali Fertility Centre LLP Ongole	Step down Subsidiary	India
30	Adiran IB Healthcare Private Limited	Step down Subsidiary	India
31	Cantown Infra Developers LLP	Step down Subsidiary	India
32	Aasraya Healthcare LLP	Step down Subsidiary	India
33	Ciigma Institute of Medical Sciences Private Limited	Step down Subsidiary*	India
34	United Ciigma Hospitals Healthcare Private Limited	Step down Subsidiary*	India
35	KIMS Kottayam Institute of Medical Sciences Private Limited (formerly known as KIMS Bellerose Institute of Medical Science Private Limited)	Step down Subsidiary*	India
36	KIMS Kollam Multi Speciality Hospital India Private Limited	Step down Subsidiary*	India
37	Spiceretreat Hospitality Services Private Limited	Step down Subsidiary*	India
38	KIMSHEALTH Executive Leisure Private Limited	Step down Subsidiary*	India
39	KIMS Al Shifa Healthcare Private Limited	Step down Subsidiary*	India
40	KIMS Nagercoil Institute of Medical Sciences Private Limited	Step down Subsidiary*	India
41	STS Holdings Limited	Step down Subsidiary*	Bangladesh
42	STS Hospital Chittagong Limited	Step down Subsidiary*	Bangladesh
43	Heart Care Institute And Research Centre (Indore) Private Limited	Step down Subsidiary*	India
44	QCIL Nagpur Private Limited	Step down Subsidiary*	India
45	Quality Health Care Services Private Limited	Joint Venture*	India
46	MIMS Infrastructure and Properties Private Limited	Associate	India
47	Alfaone Medicals Private Limited	Associate	India
48	Alfaone Retail Pharmacies Private Limited	Associate	India
49	SCL Healthcare Private Limited	Associate*	India
50	Mindriot Research and Innovation Foundation	Associate	India

* With effect from 1 July 2026, on account of amalgamation

